JNJ - Johnson & Johnson

NYSE - NYSE Delayed price. Currency in USD
132.50
-2.21 (-1.64%)
At close: 4:02PM EDT
Stock chart is not supported by your current browser
Previous close134.71
Open132.93
Bid0.00 x 1000
Ask0.00 x 800
Day's range131.75 - 133.83
52-week range121.00 - 148.99
Volume9,966,010
Avg. volume7,123,291
Market cap351.795B
Beta (3Y monthly)0.76
PE ratio (TTM)24.56
EPS (TTM)5.40
Earnings date15 Oct 2019
Forward dividend & yield3.80 (2.82%)
Ex-dividend date2019-08-26
1y target est149.17
Trade prices are not sourced from all markets
  • Johnson & Johnson CFO on the opioid crisis: 'We don’t believe we were the cause'
    Yahoo Finance11 hours ago

    Johnson & Johnson CFO on the opioid crisis: 'We don’t believe we were the cause'

    Pharmaceutical companies are facing increasing scrutiny for their alleged roles in the opioid crisis. Its next target? Johnson & Johnson (JNJ).

  • Stocks slip slightly amid trade remarks, earnings season
    Yahoo Finance11 hours ago

    Stocks slip slightly amid trade remarks, earnings season

    U.S. stocks were mixed Tuesday afternoon as investors digested a wave of signals from officials over U.S.-China trade relations and monetary policy, along with an influx of corporate earnings results and economic data.

  • Johnson & Johnson (JNJ) Q2 2019 Earnings Call Transcript
    Motley Fool12 hours ago

    Johnson & Johnson (JNJ) Q2 2019 Earnings Call Transcript

    JNJ earnings call for the period ending June 30, 2019.

  • J&J Ups Sales Forecast as Cancer Drugs Drive Growth
    Bloomberg12 hours ago

    J&J Ups Sales Forecast as Cancer Drugs Drive Growth

    (Bloomberg) -- Johnson & Johnson raised its revenue guidance for the year, as strong sales in its pharmaceutical unit helped cushion a decline in the consumer and medical technology businesses.Second-quarter adjusted earnings were $2.58 a share, topping the $2.45 average of analysts’ estimates. To read more details on the results, click here.Key InsightsThe company’s full revenue is actually down from a year prior. Part of that can be attributed to the company’s divestiture of its medical sterilization business, ASP, which it sold to Fortive Corp. earlier this year. The company was also hit badly by foreign exchange rates. Almost half of J&J’s sales come from outside the U.S., and its fastest-growing segment -- overseas pharmaceuticals -- had its growth cut nearly in half because of currency fluctuations.J&J’s drug business is the largest of the company’s three main segments and accounts for more than half of all revenue. Its cancer drugs, including Darzalex and Imbruvica, drove growth in the quarter and were up 9.8% from a year prior.Market ReactionThe shares were down 1% to $133.41 at 9:43 a.m. in New York. The stock is up 4.4% this year to date as of Monday’s close, trailing the broader market.(Corrects spelling of cancer drug Darzalex in “Key Insights” section.)To contact the reporter on this story: Riley Griffin in New York at rgriffin42@bloomberg.netTo contact the editor responsible for this story: Drew Armstrong at darmstrong17@bloomberg.netFor more articles like this, please visit us at bloomberg.com©2019 Bloomberg L.P.

  • J&J vows to defend itself in talc, opioid lawsuits
    CNBC16 hours ago

    J&J vows to defend itself in talc, opioid lawsuits

    Johnson & Johnson vowed to defend itself against lawsuits alleging the company fueled the opioid crisis and that its namesake talc-based baby powder caused ovarian cancer and mesothelioma.

  • AbbVie (ABBV) Acquires Mavupharma to Boost Cancer Portfolio
    Zacks16 hours ago

    AbbVie (ABBV) Acquires Mavupharma to Boost Cancer Portfolio

    AbbVie (ABBV) buys Mavupharma to develop novel treatments for cancer using the latter's STING signaling pathway.

  • Better-Than Expected Retail Sales in June
    Zacks16 hours ago

    Better-Than Expected Retail Sales in June

    Better-Than Expected Retail Sales in June

  • Zacks17 hours ago

    J&J (JNJ) Beats on Q2 Earnings, Ups 2019 Sales Growth View

    J&J (JNJ) beats estimates for both earnings and sales in the second quarter of 2019 and raises 2019 guidance for operational sales growth for the second time this year.

  • Retail Sales Up, Import Prices Down, Q2 Earnings Solid
    Zacks17 hours ago

    Retail Sales Up, Import Prices Down, Q2 Earnings Solid

    Retail Sales outperformed, Imports & Exports were lower, and JPM, WFC, GS and JNJ outperformed earnings expectations.

  • MarketWatch17 hours ago

    Goldman's stock rally helps keep Dow positive

    Shares of Goldman Sachs Group Inc. surged 2.3% in morning trading after big second-quarter profit and revenue beats, with the price gain enough to keep the Dow Jones Industrial Average in positive territory. The stock rose $4.88, which would add about 33 points to the Dow's price, which is up 7 points. For the other Dow earnings reporters, J.P. Morgan Chase & Co.'s stock slipped 41 cents, or 0.4%, and Johnson & Johnson shares gave up $1.60, or 1.2%; combined, those declines would shave about 14 points off the Dow's price.

  • MarketWatch17 hours ago

    Stocks pull back from record levels as earnings season picks up steam

    Stocks got off to a slightly lower start Tuesday as investors digested a stream of earnings reports, including results from Dow components Johnson & Johnson and Goldman Sachs Group Inc. . The Dow Jones Industrial Average fell around 7 points, or less than 0.1%, to 27,352, while the S&P 500 was off 0.1% at 3,011.12. The Nasdaq Composite fell 0.1% to 8,245.28. All three major indexes eked out record finished in subdued trading on Monday. Shares of Goldman Sachs were up 0.9%, while Johnson & Johnson shares fell 1.7%. Both companies topped earnings forecasts.

  • Stocks - JP Morgan, Wells Fargo Fall Premarket; J&J, Goldman Sachs Rise
    Investing.com18 hours ago

    Stocks - JP Morgan, Wells Fargo Fall Premarket; J&J, Goldman Sachs Rise

    Investing.com - Stocks in focus in premarket trading on Tuesday:

  • Johnson & Johnson (JNJ) Tops Q2 Earnings and Revenue Estimates
    Zacks18 hours ago

    Johnson & Johnson (JNJ) Tops Q2 Earnings and Revenue Estimates

    Johnson & Johnson (JNJ) delivered earnings and revenue surprises of 6.61% and 1.17%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

  • J&J warns of hit from generic drugs in third quarter, shares fall
    Reuters20 hours ago

    J&J warns of hit from generic drugs in third quarter, shares fall

    While J&J's pharmaceuticals unit has in recent years cushioned the impact of relatively slow growth in the company's medical device and consumer units, some of its older drugs have been hurt by competition from cheaper copies. "We expect the largest impacts from generics and biosimilars for the year in our pharmaceutical business to occur in the third quarter," Chief Financial Officer Joseph Wolk said on a conference call. Sales of prostate cancer treatment Zytiga fell 23% in the quarter, hurt by generic copies, and sales of J&J's blockbuster arthritis drug Remicade fell 16%, impacted by biosimilar rivals.

  • CNBC19 hours ago

    Stocks making the biggest moves premarket: Goldman Sachs, JP Morgan, J&J, KeyCorp & more

    These are the stocks posting the largest moves before the bell.

  • Johnson & Johnson Lifts Sales Guidance After Q2 Earnings Beat
    Investing.com19 hours ago

    Johnson & Johnson Lifts Sales Guidance After Q2 Earnings Beat

    Investing.com - Johnson & Johnson (NYSE:JNJ) lifted its annual sales outlook for the year after reporting second-quarter earnings that beat consensus on the top and bottom line.

  • CNBC19 hours ago

    What to watch today: Bank earnings, tech hearings on Capitol Hill, and alleged Tesla shortcuts

    U.S. stock futures point to a mixed open after a day of small gains kept the record closes going on Wall Street.

  • MarketWatch20 hours ago

    Shares of J&J up 0.8% after earnings and revenue beat

    Shares of Johnson & Johnson rose 0.8% in premarket trade Tuesday after the health-products giant reported second-quarter earnings and revenue that beat Wall Street expectations. Profit for the latest quarter rose to $5.607 billion, or $2.08 per share, from $3.954 billion, or $1.45 per share, a year ago. Adjusted EPS was $2.58 per share, beating the FactSet consensus of $2.46 per share. Revenue fell to $20.562 billion from $20.830 billion in the year-earlier quarter, but beat the FactSet consensus of $20.293 billion. Sales from J&J's consumer business rose to $3.544 billion from $3.504 billion a year ago, while the company's pharmaceuticals segment brought in $10.529 billion, up from $10.354 billion a year ago. J&J's medical devices business brought in $6.489 billion, down from $6.972 billion a year ago. J&J boosted its 2019 sales outlook to between $80.8 billion and $81.6 billion from between $80.4 billion and $81.2 billion. The company also reaffirmed its full-year adjusted EPS of between $8.53 and $8.63 per share. Shares of J&J have gained 4.4% in the year to date, while the Dow Jones Industrial Average has gained 17.3% and the S&P 500 has gained 20.2%.

  • Johnson & Johnson falls despite 42% profit spike amid talc, opioid litigation fears
    CNBC20 hours ago

    Johnson & Johnson falls despite 42% profit spike amid talc, opioid litigation fears

    Johnson & Johnson's profit jumped 42% in the second quarter, with all three of the sprawling health-care company's businesses performing better than Wall Street expected.

  • The 2 Safest Dividend Stocks on the Planet
    Motley Fool21 hours ago

    The 2 Safest Dividend Stocks on the Planet

    These brand-name behemoths are head and shoulders above their dividend-paying competition.

  • J&J Submits BLA for Subcutaneous Formulation of Darzalex
    Zacks2 days ago

    J&J Submits BLA for Subcutaneous Formulation of Darzalex

    Johnson & Johnson (JNJ) submits a BLA to the FDA, seeking approval for a subcutaneous formulation of its multiple myeloma drug.

  • AstraZeneca's Farxiga Gets CRL from FDA for Type I Diabetes
    Zacks2 days ago

    AstraZeneca's Farxiga Gets CRL from FDA for Type I Diabetes

    AstraZeneca's (AZN) SGLT2 inhibitor, Farxiga, gets CRL from the FDA for a regulatory application seeking label expansion as a treatment for type I diabetes.

  • Opioid 'kingpin' J&J fuelled epidemic, Oklahoma argues at trial's end
    Reuters2 days ago

    Opioid 'kingpin' J&J fuelled epidemic, Oklahoma argues at trial's end

    Lawyers for the state of Oklahoma on Monday compared Johnson & Johnson to a drug cartel leader as they sought to hold the drugmaker responsible for fuelling the U.S. opioid epidemic in the first trial to result from lawsuits over the crisis. Lawyers for the state, including Attorney General Mike Hunter, told a judge in Norman, Oklahoma that J&J's "greed" led the drugmaker to carry out a years-long marketing effort that caused "utter confusion" about the addictive painkillers' risks. Brad Beckworth, a lawyer for the state, said J&J knew opioids were harmful, yet minimized the risk of addiction in their marketing, resulting in a surge in overdose deaths as doctors overprescribed the drugs and they flooded the state.

By using Yahoo you agree that Yahoo and partners may use Cookies for personalisation and other purposes